A5004895242- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Single-cell and spatial transcriptomics
- Pancreatic and Hepatic Oncology Research
- Lymphoma Diagnosis and Treatment
- Hippo pathway signaling and YAP/TAZ
- CRISPR and Genetic Engineering
- Computational Drug Discovery Methods
- SARS-CoV-2 and COVID-19 Research
- Educational Curriculum and Learning Methods
- COVID-19 Clinical Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Ferroptosis and cancer prognosis
- Immune Cell Function and Interaction
- Bioinformatics and Genomic Networks
- AI in cancer detection
- Immune cells in cancer
- PARP inhibition in cancer therapy
- Epigenetics and DNA Methylation
- Lung Cancer Treatments and Mutations
- RNA modifications and cancer
- Chemokine receptors and signaling
- Cancer Cells and Metastasis
- Pluripotent Stem Cells Research
Center for Cancer Research
2018-2025
National Institutes of Health
2020-2025
National Cancer Institute
2018-2025
Discovery Institute
2023-2025
Sanford Burnham Prebys Medical Discovery Institute
2023-2025
University of Cambridge
2024
Royal Marsden Hospital
2024
Royal Ottawa Mental Health Centre
2024
Weatherford College
2024
University of Maryland, College Park
2018-2023
Anticancer therapies have been limited by the emergence of mutations and other adaptations. In bacteria, antibiotics activate SOS response, which mobilizes error-prone factors that allow for continuous replication at cost mutagenesis. We investigated whether treatment lung cancer with EGFR inhibitors (EGFRi) similarly engages hypermutators. cycling drug-tolerant persister (DTP) cells in EGFRi-treated patients presenting residual disease, we observed upregulation GAS6, whereas ablation GAS6's...
Lung cancer is the leading cause of cancer-related deaths worldwide. The paralogous transcriptional cofactors Yes-associated protein (YAP) and coactivator with PDZ-binding motif (TAZ, also called WWTR1), main downstream effectors Hippo signal transduction pathway, are emerging as pivotal determinants malignancy in lung cancer. Traditionally, studies have tended to consider YAP TAZ functionally redundant similar biological impact. However, there growing evidence that each them possesses...
The COVID-19 pandemic caused by SARS-CoV-2 has is a global health challenge. Angiotensin-converting enzyme 2 (ACE2) the host receptor for entry. Recent studies have suggested that patients with hypertension and diabetes treated ACE inhibitors (ACEIs) or angiotensin blockers higher risk of infection as these drugs could upregulate ACE2, motivating study ACE2 modulation in current clinical use. Here, we mined published datasets to determine effects hundreds clinically approved on expression....
Until coronavirus disease 2019 (COVID-19) drugs specifically developed to treat COVID-19 become more widely accessible, it is crucial identify whether existing medications have a protective effect against severe disease. Toward this objective, we conducted large population study in Clalit Health Services (CHS), the largest healthcare provider Israel, insuring over 4.7 million members.
Abstract The FDA has recently approved a high tumor mutational burden (TMB-high) biomarker, defined by ≥10 mutations/Mb, for the treatment of solid tumors with pembrolizumab, an immune checkpoint inhibitor (ICI) that targets PD1. However, recent studies have shown this TMB-high biomarker is only able to stratify ICI responders in subset cancer types, and mechanisms underlying observation remained unknown. microenvironment (TME) may modulate stratification power TMB (termed power),...
Abstract Recent studies have reported that genome editing by CRISPR–Cas9 induces a DNA damage response mediated p53 in primary cells hampering their growth. This could lead to selection of with pre-existing mutations. In this study, employing an integrated computational and experimental framework, we systematically investigated the possibility additional cancer driver mutations during CRISPR-Cas9 gene editing. We first confirm previous findings for CRISPR-Cas9. next demonstrate similar ,...
Precision oncology is gradually advancing into mainstream clinical practice, demonstrating significant survival benefits. However, eligibility and response rates remain limited in many cases, calling for better predictive biomarkers.We present ENLIGHT, a transcriptomics-based computational approach that identifies clinically relevant genetic interactions uses them to predict patient's variety of therapies multiple cancer types without training on previous treatment data. We study ENLIGHT two...
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy and largely refractory to available treatments. Identifying key pathways associated with disease aggressiveness therapeutic resistance may characterize candidate targets improve patient outcomes. We used strategy of examining the tumors from subset PDAC cohorts worst survival understand underlying mechanisms aggressive progression identify molecular potential significance. Non-negative matrix factorization (NMF) clustering, using...
Gene context-essentiality assessment supports precision oncology opportunities. The variability of gene effects inference from loss-of-function screenings across models and technologies limits identifying robust hits. We propose a computational framework named PRODE that integrates with protein–protein interactions to generate neighborhood-informed essential (NIE) context (NICE) scores. It outperforms the canonical effect approach in recovering missed genes shRNA screens prioritizing...
Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of hematological malignancies. However, its application to solid tumors remains limited by heterogeneity and on-target, off-tumor toxicities. One critical emerging approach combat this challenge is logic-gated multi-antigen targeting, for both enhanced safety efficacy. Methods: To address these challenges, we developed a novel genetic algorithm, termed LogiCAR, applied it analyze more than...
Telomere dysfunction is a key hallmark of aging linked to numerous age—related diseases including cardiovascular disorders, pulmonary fibrosis, and metabolic syndromes. Despite decades research yielding strong evidence linking telomere biology processes, the field faces critical bottleneck: current measurement methods require specialized molecular techniques that prevent large—scale studies clinical implementation. Here we present TLPath, novel deep learning framework extracts normal tissue...
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematological malignancies. However, its application in solid tumors remains limited because single targets are unlikely to suffice due tumor heterogeneity and off-tumor toxicities. To overcome these obstacles, we developed LogiCAR designer, a computational approach that utilizes single-cell transcriptomics data from patient systematically identify cancer-specific circuits with logic gates ("AND," "OR," "NOT")...
<p>Supplementary Figure 3</p>
<p>Supplementary Figure 1</p>
<p>Supplementary Figure 10</p>
<p>Supplementary Figure 5</p>
<p>Supplementary Figure 11</p>
<p>Comprehensive lists of all signatures predicting patient ICB response.</p>